Overview Acute myeloid leukemia (AML) is an aggressive blood cancer that grows rapidly and comes back even after initial treatment. Traditional treatments such as chemotherapy and bone marrow transplant can be very harsh and are not always effective – especially during relapses. The approval of the menin inhibitor ziftomenib is a major advance in personalized …
Introduction: A New Era of Cancer Treatment (SEO-Optimized) The best new oncology drugs approved by FDA in 2024–25 represent some of the biggest milestones in cancer therapy—especially for pharmacy students, clinicians, researchers, and competitive exam aspirants. Cancer treatment is rapidly evolving with next-gen immunotherapies, targeted therapies, bispecific antibodies, ADCs (antibody–drug conjugates), and precision medicines leading …
The year 2025 marked a significant milestone in cancer treatment, redefining how physicians approach immune-based therapies. With the approval of several Next Gen Immunotherapy Approved in 2025, the oncology landscape shifted toward more precise, accessible, and patient-friendly interventions. These innovations go beyond first-generation immunotherapies (such as classic checkpoint inhibitors) and introduce improved cell therapies, bispecific …
Introduction Antibiotic resistance is increasing globally, creating an urgent need for new, effective and orally active antimicrobial therapies. One such advance is sulopenem etzadroxil probenecid, a combination therapy designed to combat complex bacterial infections and offers convenient oral administration. This potent antibiotic combination is gaining attention for its effectiveness against multidrug-resistant pathogens, particularly in urinary …
Introduction: Why “Nitisinone FDA Approval” Is Making Headlines The topic of nitisinone FDA approval has been hotly debated following the recent decision by the US Food and Drug Administration (FDA) to approve Harliku (nitisinone) for the treatment of a rare metabolic disorder – alkaptonuria (AKU) – in 2025. Originally introduced in 2002 under the brand …
Introduction Belzutifan, marketed under the brand name Velireg, has emerged as a promising drug in the fight against certain types of cancer, particularly renal cell carcinoma (RCC) and tumors associated with von Hippel-Lindau (VHL) disease. While its benefits in slowing tumor growth are significant, understanding the side effects of belzutifan is equally important to ensure …
Mitochondrial diseases are among the most challenging conditions to diagnose and treat, largely due to their genetic complexity and muscular energy dependence. One such disorder – thymidine kinase 2 (TK2) deficiency – is known as an extremely rare mitochondrial DNA depletion and deletion syndrome caused by mutations in the nuclear TK2 gene. Recent advances in …
Introduction: A New Chapter in Cancer Immunotherapy Cancer treatment has changed dramatically over the past few decades, moving beyond chemotherapy and radiation to therapies that harness the body’s own immune system. Among these next-generation approaches, Lifileucel immunotherapy is being hailed as a personalized, cell-based treatment that offers hope to patients with advanced cancer – especially …
Introduction In the evolving field of oncology, hormonal therapy is an important part of breast cancer treatment. Among the latest advances is Elacestrant , an oral selective estrogen receptor degrader (SERD) that represents a significant leap forward in the management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer. Understanding the Elacestrant mechanism of action is …
Introduction In the fast-paced world of cancer treatment, Imdelltra (tarlatamab-DLE) is emerging as a groundbreaking immunotherapy. Approved by the FDA for patients with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after platinum-based chemotherapy, Imdelltra offers a new lifeline. However, beyond the clinical data, there is an essential operational aspect – the Imdelltra J …
